Tolvaptan Tablet
Product Images NDC 60505-4318

Mean serum sodium levels were evaluated in a sample of 213 individuals who received Toaptan 15-80mg and in a sample of 203 individuals who received placebo. The mean serum sodium level for those who received Toaptan was 1427¢ SD, mEq/L, which was significantly different from the serum sodium level for those who received placebo (140, p<0wor vs placebo). The evaluation was conducted at baseline and on the 1st, 2nd, 3rd, 4th, and 7th day follow-up appointments. No further information or context is available from the given text.*

This is a clinical trial report evaluating the effects of Tolvaptan on mean serum sodium levels in patients. Results suggest significant improvement in serum sodium levels compared to placebo. The chart shows baseline levels and levels recorded over different days of treatment.*

This appears to be a chart showing the mean serum sodium levels (in milliequivalents per liter, or mEgL) for a group of 111 individuals taking tolvaptan at a dose of 15.60 milligrams. The levels are compared to a baseline measurement, and there is a statistically significant difference between the two (indicated by the asterisk and p-value). The chart also includes measurements taken at various time points, including before and after a "washout" period.*

Eashtablets are tablets that contain 30 mg of toluaptan. They should be stored at a temperature of 25°C (77°F) with permitted excursions to 15°C to 30°C (59°F to 86°F) according to ISP Controlled Room Temperature guidelines. The usual dosage details and instructions can be found on the package insert. This particular pack contains 30 tablets, with the NDG number 60505-4318-3. Tolvaptan is the active ingredient and this medication must be initiated while in the hospital. The enclosed guide should be dispensed to each individual patient by the pharmacist. This product is manufactured by Apotex Corp. The address listed is "aneren by Aot st v Ebianiessn o, cota o T thesnmiese 1w HaEEDE b e Waston, s 325".*